Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Advances in experimental medicine and biology, December 2015
Priyanga Wijesinghe Ph.D., Aliccia Bollig-Fischer Ph.D., Priyanga Wijesinghe, Aliccia Bollig-Fischer
Aamir Ahmad, Shirish M. Gadgeel
Lung cancer is the leading cause of cancer-related deaths in the United States and the 5-year overall survival outlook for a patient has not improved in several decades. Recently, however, molecular and genomic profiling of the lung tumors has revealed recurring somatic mutations. As a result the therapeutic landscape of lung cancer is undergoing a paradigm shift from a purely histology-based understanding of the disease to subtype distinctions based on tumor genetics, which has launched cancer-specific, mechanism-based targeted therapies with clear benefit to patients. While targeted therapy advancements are being made at an ever increasing rate, a new challenge in the form of drug resistance has also emerged. This review summarizes the current literature for these issues.
|Readers by professional status||Count||As %|
|Student > Ph. D. Student||1||17%|
|Student > Bachelor||1||17%|
|Lecturer > Senior Lecturer||1||17%|
|Student > Postgraduate||1||17%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||4||67%|
|Biochemistry, Genetics and Molecular Biology||2||33%|